Research Publications

Wednesday or Thursday MorningsBy special appointment07440 171960appointments@karlgaffney.co.uk

Professor Karl Gaffney has considerable experience in clinical research, having published over 100 original papers and abstracts. Specific interests include Ankylosing Spondylitis, Rheumatoid Arthritis and Osteoporosis. Dr Gaffney leads a research team in Ankylosing Spondylitis and is a regular invited speaker at National and International meetings.

Research PublicationsBooksWebsites

Publications

Publication	Author(s)	Date
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial	Abhishek Abhishek, Nicholas Peckham, Corinna Pade, Joseph M Gibbons, Lucy Cureton, Anne Francis, Vicki Barber, Jennifer AE Williams, Duncan Appelbe, Lucy Eldridge, Patrick Julier, Daniel M Altmann, James Bluett, Tim Brooks, Laura C Coates, Ines Rombach, Amanda Semper, Ashley Otter, Ana M Valdes, Jonathan S Nguyen-Van-Tam, Hywel C Williams, Rosemary J Boyton, Áine McKnight, Jonathan A Cook, Ira Pande, Ting Seng Tang, Gui Tran, Alison Layton, Elizabeth Price, Lindsay Whittam, Srinivasan Venkatachalam, Gwenan Huws, Arthur Pratt, Nick J Reynolds, Taryn Youngstein, David A Walsh, Theresa Joseph, Rengi Mathew, Stamatios Oikonomou, Catherine Gwynne, Rory Crowder, Vadivelu Saravanan, Alaa Mustafa, Cristina Tacu, Emmanuel George, Thomas Batty, Anushka Soni, Sarah Horton, Karl Gaffney, Nicola Gullick, Agnieszka Lapin, Sarah Bingham, Ayesha Madan, Chris Holroyd, May Lwin, Salema Khalid, Mike Green, Laura Hunt, Nicola Alcorn, Rob Ellis, Samantha Hider, Ala Hassan, Karen Douglas, Gen Nen Ho, Kirsty Levasseur, John Pradeep, Ceril Rhys-Dillon, Catrin Jones	12 December 2023
CO49 A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Ixekizumab at 52 Weeks for the Treatment of Radiographic Axial Spondyloarthritis	H Thom, K Gaffney, M Mørup, V Taieb, D Willems, WP Maksymowych	1 December 2023
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease	Ulf Müller-Ladner, Axel Dignass, Karl Gaffney, Deepak Jadon, Marco Matucci-Cerinic, Triana Lobaton, Philippe Carron, Javier P Gisbert, Ira Pande, Maximilian Utzinger, Janet Addison	1 November 2023
Evaluation of the current use of MRI to aid the diagnosis of axial spondyloarthritis in the UK: results from a freedom of information request	T. J. P. Bray; J. Eddison; J. Hamilton; D. Webb; A. Bennett; P. M. Machado; Karl Gaffney; R. Sengupta; M. A. Hall-Craggs; H. Marzo-Ortega	26 October 2023
Evaluation of the current use of MRI to aid the diagnosis of axial spondyloarthritis in the UK: results from a freedom of information request	TJP Bray, Joe Eddison, Jill Hamilton, Dale Webb, Alexander Bennett, PM Machado, Karl Gaffney, Raj Sengupta, MA Hall-Craggs, Helena Marzo-Ortega	5 October 2023
Diagnostic delay in axial spondylarthritis: A lost battle?	Rosemarie Barnett, Karl Gaffney, Raj Sengupta	30 August 2023
Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA	Karl Gaffney, Nicola Gullick, Kirsten MacKay, Yusuf Patel, Raj Sengupta, Tom Sheeran, Louise Hemmings, Paula Pamies	12 August 2023
Identifying Axial spondyloarthritis in patients with inflammatory bowel disease using computed tomography	Chong SE Lim, Louise Hamilton, Samantha BL Low, Andoni Toms, Alexander Macgregor, Karl Gaffney	1 July 2023
Prevalence of undiagnosed axial spondyloarthritis in inflammatory bowel disease patients with chronic back pain: secondary care cross-sectional study	Chong Seng Edwin Lim, Mark Tremelling, Louise Hamilton, Matthew Kim, Alexander Macgregor, Tom Turmezei, Karl Gaffney	1 April 2023
Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons	Nurullah Akkoç, Carlos H Arteaga, Simone E Auteri, Marissa Betts, Kyle Fahrbach, Mindy Kim, Sandeep Kiri, Binod Neupane, Karl Gaffney, Philip J Mease	1 April 2023
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials	Désirée Van Der Heijde, Atul Deodhar, Xenofon Baraliakos, Matthew A Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, Alicia M Ellis, Carmen Fleurinck, Karl Gaffney, Lianne S Gensler, Nigil Haroon, Marina Magrey, Walter P Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martin Rudwaleit, Julie Shepherd-Smith, Tetsuya Tomita, Filip Van den Bosch, Thomas Vaux, Huji Xu	1 April 2023
P194 Bimekizumab is associated with improvement in quality of life in patients across the full spectrum of axial spondyloarthritis at week 16: results from two phase 3 studies	Neil McKay, Alexander Bennett, Nicola Goodson, Carmen Fleurinck, Christine de la Loge, Ute Massow, Vanessa Taieb, Helena Marzo-Ortega, Karl Gaffney	1 April 2023
P193 Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies	Karl Gaffney, Neil McKay, Raj Sengupta, Carmen Fleurinck, Christine de la Loge, Ute Massow, Vanessa Taieb, Sizheng Steven Zhao, Helena Marzo-Ortega	1 April 2023
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.	Joshua J Solomon, Sonye K Danoff, Felix A Woodhead, Shelley Hurwitz, Rie Maurer, Ian Glaspole, Paul F Dellaripa, Bibek Gooptu, Robert Vassallo, P Gerard Cox, Kevin R Flaherty, Huzaifa I Adamali, Michael A Gibbons, Lauren Troy, Ian A Forrest, Joseph A Lasky, Lisa G Spencer, Jeffrey Golden, Mary Beth Scholand, Nazia Chaudhuri, Mark A Perrella, David A Lynch, Daniel C Chambers, Martin Kolb, Cathie Spino, Ganesh Raghu, Hilary J Goldberg, Ivan O Rosas, Shana Haynes-Harp, Fernando Poli, Coimbatore Sree Vidya, Rebecca R Baron, Timothy Clouser, Tracy Doyle, Anthony Maeda, Kristin B Highland, Jemima F Albayda, Sarah E Collins, Karthik S Suresh, John M Davis, Andrew H Limper, Isabel Amigues, Kristina Eliopoulos, Jeffery J Swigris, Stephen Humphries, John C Huntwork, Chris Glynn, Steve R Duncan, Maria I Danila, Marilyn K Glassberg, Elana M Oberstein, Elizabeth A Belloli, Linda Briggs, Vivek Nagaraja, Linda Cholewa, Donna DiFranco, Edward Green, Christie Liffick, Tanvi Naik, Genevieve Montas, Dorota Lebiedz-Odrobina, Reba Bissell, Mark Wener, Lisa H Lancaster, Leslie J Crawford, Karmela Chan, Robert J Kaner, Alicia Morris, Xiaoping Wu, Nader A Khalidi, Christopher J Ryerson, Alyson W Wong, Charlene D Fell, Sharon A LeClercq, Mark Hyman, Shane Shapera, Shikha Mittoo, Shireen Shaffu, Karl Gaffney, Andrew M Wilson, Shaney Barratt, Harsha Gunawardena, Rachel K Hoyles, Joel David, Namrata Kewalramani, Toby M Maher, Philip L Molyneaux, Maria A Kokosi, Matthew J Cates, Mandizha Mandizha, Abdul Ashish, Gladstone Chelliah, Helen Parfrey, Muhunthan Thillai, Josephine Vila, Sophie V Fletcher, Paul Beirne, Clair Favager, Jo Brown, Julie K Dawson, Pilar Rivera Ortega, Sahena Haque, Pippa Watson, Jun K Khoo, Karen Symons, Peter Youssef, John A Mackintosh	1 January 2023
Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope	Sizheng Steven Zhao, Stephanie R Harrison, Antoni Chan, Nick Clarke, Charlotte Davis, Joe Eddison, William J Gregory, Gareth T Jones, Helena Marzo-Ortega, Daniel J Murphy, Virinderjit Sandhu, Raj Sengupta, Stefan Siebert, Ben Thompson, Dale Webb, Max Yates, Karl Gaffney	1 January 2023